Clinical trials: Primary Headache Disorders
Migraine
Use of the Avulux® Lenses as an Aid in Reducing the Impact of Migraine Headaches
The purpose of this research is to assess how well the Avulux® migraine lenses work in reducing the impact of migraine headaches as measured by improvement in an 11-point pain scale after two and four hours of device application…
- Trial name
- NCT04341298
- Testing
- 11-point pain scale, Headache diary, Avulux®
- Where
- 3 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Avulux, Inc.
Migraine Disorders
Biomarker Study in Participants With Migraine
This is a study of participants with a diagnosis of migraine who completed another clinical trial NCT02163993. The participants received either LY2951742 or placebo.
- Trial name
- NCT02766517
- Testing
- Capsaicin
- Where
- 14 sites in United States
- Volunteers
- 37 people
- Sponsor
- Eli Lilly and Company
Migraine, Healthy
Molecular and Functional PET-fMRI Measures of Analgesia in Migraine
The placebo effect is a phenomenon that has experienced major advances of its understanding in the last decade. However, mechanisms of placebo analgesia in chronic pain patients have yet to be compared to healthy subjects.
- Trial name
- NCT01970943
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Migraine Disorders
An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine
This is an observational study to describe the long term use of Onabotulinumtoxin A (BOTOX®) as prescribed by the physician for headache prophylaxis in adults with chronic migraine. All treatment decisions lie with the physician.
- Trial name
- NCT01686581
- Testing
- botulinum toxin Type A
- Where
- 77 sites in Germany, Italy and 5 more
- Volunteers
- 641 people
- Sponsor
- Allergan
Migraine Headaches
Prospective, Multi-Center Evaluation of the Efficacy of Peripheral Trigger Decompression Surgery for Migraine Headaches
According to the peripheral trigger theory of migraine headaches, nociceptive inputs from irritated or compressed cranial nerve branches can lead to neurovascular changes in the brain that cause migraine headaches.
- Trial name
- NCT02351544
- Testing
- Botulinum Toxin Type A, Surgery, Daily headache diary
- Where
- 6 sites in United States
- Volunteers
- 44 people
- Sponsor
- Ohio State University
Migraine
Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine
The purpose of this pilot study is to assess feasibility and clarify the design of future study(ies) to support marketing approval of the GammaCore™ device for the treatment and/or prevention of migraine symptoms.
- Trial name
- NCT01532830
- Testing
- n-VNS
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- ElectroCore INC
Migraine
Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine
This is a prospective, randomized, vehicle-controlled, double-blind, multi-center study assessing the safety, tolerability, and efficacy of B244 delivered as an intranasal spray for preventive treatment in subjects with episodic…
- Trial name
- NCT03488563
- Testing
- B244, Vehicle
- Where
- 22 sites in United States
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- AOBiome LLC
Migraine
Non-invasive Neurostimulation for the Relief of Migraine
The purpose of this feasibility study is to gather preliminary information on the safety and effectiveness of patient self-administration of a noninvasive neurostimulation of the vagus nerve using the GammaCore device for the…
- Trial name
- NCT03410628
- Testing
- gammaCore
- Volunteers
- 21 people
- Sponsor
- ElectroCore INC
Migraine
Initiating Early Control of Migraine Pain and Associated Symptoms
AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan, which is being developed for the acute treatment of migraine with or without aura in adults.
- Trial name
- INTERCEPT (NCT04163185)
- Testing
- AXS-07 (MoSEIC meloxicam and rizatriptan)
- Where
- 41 sites in United States
- Volunteers
- 302 people
- Sponsor
- Axsome Therapeutics, Inc.
Migraine, With or Without Aura
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention
This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and…
- Trial name
- NCT02848326
- Testing
- Atogepant
- Where
- 75 sites in United States
- Volunteers
- 834 people
- Sponsor
- Allergan
Migraine
Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks
Greater Occipital Nerve Blocks (GONB) are a common procedure used for the treatment of headache. The GONB procedure involves a series of injections into the greater occipital nerve (a spinal nerve located at the back of your…
- Trial name
- NCT00329732
- Testing
- 0.5% bupivicaine and 2% lidocaine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Thomas Jefferson University
Migraine Disorders
Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)
This record describes pooled data for three extension studies: MK-0462-022 (NCT00897949); MK-0462-025 (NCT00899379); and MK-0462-029 (NCT00897104).
- Trial name
- NCT01286207
- Testing
- Rizatriptan 5 mg, Rizatriptan 10 mg, Standard Care
- Volunteers
- 1,959 people
- Sponsor
- Organon and Co
Migraine, Chronic Migraine
Introvision for Migraine and Headaches
To evaluate the effect of Introvision, a mental and emotional self-regulation-technique developed by Angelika C. Wager, as migraine preventative compared to a waiting list group.
- Trial name
- IntroMig (NCT03507400)
- Testing
- Introvision: mental and emotional self-regulation
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Migraine Disorder
An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine
An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine
- Trial name
- PREVAIL (NCT02985398)
- Testing
- ALD403 (Eptinezumab)
- Where
- 20 sites in United States
- Volunteers
- 128 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine
Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function
This is a multi-center, open-label, non-randomized, parallel-group, adaptive, single dose study. This study will enroll up to 32 participants using an adaptive design that can include up to 3 groups of 8 participants with…
- Trial name
- NCT03009162
- Testing
- Lasmiditan
- Where
- 2 sites in Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention
To evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days, in adults with episodic migraine.
- Trial name
- ARISE (NCT02483585)
- Testing
- Erenumab
- Where
- 76 sites in United States, Denmark and 6 more
- Volunteers
- 577 people
- Sponsor
- Amgen
Migraine Headache
A Study in Migraine Prevention
The primary objective of this study is to measure the change in frequency of migraine attacks per 28 days in migraine patients being treated orally with LY2300559 for 12 weeks.
- Trial name
- NCT01184508
- Testing
- LY2300559
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Migraine
Acetaminophen and Ibuprofen With and Without Magnesium and Primary Migraine in Childhood
Aim: The purpose of this study was to evaluate both the effects of ibuprofen and/or acetaminophen for the acute treatment of primary migraine in children in or out prophylactic treatment with magnesium.
- Trial name
- NCT01756209
- Testing
- Magnesium 400Mg, Ibuprofen 10 mg/kg, acetaminophen 15 mg/kg
- Where
- Italy
- Volunteers
- 160 people
- Sponsor
- University of Catanzaro
Migraine Disorders
Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults
This study will evaluate the efficacy, safety and tolerability of prophylactic (preventative) treatment with BOTOX® (onabotulinumtoxinA) compared to topiramate in adults with chronic migraine.
- Trial name
- NCT02191579
- Testing
- onabotulinumtoxinA, Topiramate
- Where
- 32 sites in United States
- Volunteers
- 282 people
- Sponsor
- Allergan
Migraine, With or Without Aura
Safety and Efficacy in Adult Subjects With Acute Migraines
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
- Trial name
- NCT03237845
- Testing
- Rimegepant
- Where
- 50 sites in United States
- Volunteers
- 1,499 people
- Sponsor
- Pfizer